Last reviewed 2026-05-14 · How we verify

Heparin Sodium In Plastic Container (Heparin Sodium)

Fresenius Kabi · FDA-approved approved Oligosaccharide Quality 65/100

Heparin Sodium In Plastic Container (generic name: Heparin Sodium) is a Anticoagulant Oligosaccharide drug developed by Fresenius Kabi. It is currently FDA-approved (first approved 1939) for Deep Vein Thrombosis with Pulmonary Embolism, Deep venous thrombosis, Disseminated intravascular coagulation.

Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa.

Heparin Sodium Injection is a parenteral anticoagulant indicated for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and other thromboembolic conditions. It works by enhancing Antithrombin III activity to inhibit coagulation factors Xa and IIa, with immediate onset after intravenous administration and dose-dependent half-life of 0.5-2 hours. Major risks include heparin-induced thrombocytopenia, bleeding complications, and significant drug interactions with antiplatelet agents and oral anticoagulants requiring careful monitoring. Heparin remains a cornerstone anticoagulant therapy with established clinical efficacy, though newer anticoagulants have expanded treatment options.

At a glance

Generic name	Heparin Sodium
Sponsor	Fresenius Kabi
Drug class	Anticoagulant
Target	Antithrombin III; Coagulation Factors Xa and IIa
Modality	Oligosaccharide
Phase	FDA-approved
First approval	1939

Mechanism of action

Heparin interacts with the naturally occurring plasma protein Antithrombin III, inducing a conformational change that markedly enhances its serine protease activity. This enhanced activity inhibits activated coagulation factors involved in the clotting sequence, particularly Factor Xa and Factor IIa (thrombin). Small amounts of heparin inhibit Factor Xa, while larger amounts inhibit thrombin. Heparin also prevents the formation of stable fibrin clots by inhibiting the activation of the fibrin stabilizing factor. Importantly, heparin does not have fibrinolytic activity and therefore cannot lyse existing clots.

Approved indications

Deep Vein Thrombosis with Pulmonary Embolism
Deep venous thrombosis
Disseminated intravascular coagulation
Maintain Patency of Indwelling Vascular Catheter
Non-Q wave myocardial infarction
Peripheral Arterial Thromboembolism Prevention
Peripheral arterial embolism
Prevention of Cardiac Ischemia in Unstable Angina
Prevention of Ischemic Complications of Non-Q Wave MI
Prevention of Recurrent Venous Thrombosis Associated with Malignancy
Prevention of deep vein thrombosis
Pulmonary Thromboembolism Prevention
Pulmonary thromboembolism

Common side effects

Bleeding complication
Wound complication

Drug interactions

Oral anticoagulants (dicumarol, warfarin sodium)
Platelet inhibitors (NSAIDs, dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists)
Digitalis, tetracyclines, nicotine, antihistamines
Intravenous nitroglycerin
Antithrombin III (human)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Heparin Sodium In Plastic Container CI brief — competitive landscape report
Heparin Sodium In Plastic Container updates RSS · CI watch RSS
Fresenius Kabi portfolio CI

Frequently asked questions about Heparin Sodium In Plastic Container

What is Heparin Sodium In Plastic Container?

Heparin Sodium In Plastic Container (Heparin Sodium) is a Anticoagulant drug developed by Fresenius Kabi, indicated for Deep Vein Thrombosis with Pulmonary Embolism, Deep venous thrombosis, Disseminated intravascular coagulation.

How does Heparin Sodium In Plastic Container work?

Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa.

What is Heparin Sodium In Plastic Container used for?

Heparin Sodium In Plastic Container is indicated for Deep Vein Thrombosis with Pulmonary Embolism, Deep venous thrombosis, Disseminated intravascular coagulation, Maintain Patency of Indwelling Vascular Catheter, Non-Q wave myocardial infarction.

Who makes Heparin Sodium In Plastic Container?

Heparin Sodium In Plastic Container is developed and marketed by Fresenius Kabi (see full Fresenius Kabi pipeline at /company/pfizer).

What is the generic name of Heparin Sodium In Plastic Container?

Heparin Sodium is the generic (nonproprietary) name of Heparin Sodium In Plastic Container.

What drug class is Heparin Sodium In Plastic Container in?

Heparin Sodium In Plastic Container belongs to the Anticoagulant class. See all Anticoagulant drugs at /class/anticoagulant.

When was Heparin Sodium In Plastic Container approved?

Heparin Sodium In Plastic Container was first approved on 1939.

What development phase is Heparin Sodium In Plastic Container in?

Heparin Sodium In Plastic Container is FDA-approved (marketed).

What are the side effects of Heparin Sodium In Plastic Container?

Common side effects of Heparin Sodium In Plastic Container include Bleeding complication, Wound complication.

What does Heparin Sodium In Plastic Container target?

Heparin Sodium In Plastic Container targets Antithrombin III; Coagulation Factors Xa and IIa and is a Anticoagulant.

Drug class: All Anticoagulant drugs
Target: All drugs targeting Antithrombin III; Coagulation Factors Xa and IIa
Manufacturer: Fresenius Kabi — full pipeline
Indication: Drugs for Deep Vein Thrombosis with Pulmonary Embolism
Indication: Drugs for Deep venous thrombosis
Indication: Drugs for Disseminated intravascular coagulation
Compare: Heparin Sodium In Plastic Container vs similar drugs
Pricing: Heparin Sodium In Plastic Container cost, discount & access